FDA says Geodon journal ad omits risk info

Share this article:
The FDA says a professional journal ad for Pfizer's antipsychotic medication Geodon (ziprasidone mesylate) for injection omits important risk info and contains unsubstantiated superiority claims. It wants the company to submit a list of all materials to be pulled along with a plan for discontinuing its use, and Pfizer has agreed.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters